Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1979 1
1980 5
1981 5
1982 2
1983 2
1984 1
1985 1
1986 1
1987 1
1989 1
1990 1
1996 1
1998 4
1999 4
2000 2
2001 2
2002 2
2003 5
2004 3
2005 9
2006 3
2007 5
2008 8
2009 3
2010 4
2011 6
2012 4
2013 8
2014 8
2015 8
2016 9
2017 3
2018 2
2019 6
2020 9
2021 4
2022 4
2023 9
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Organoid cultures derived from patients with advanced prostate cancer.
Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y. Gao D, et al. Among authors: slovin sf. Cell. 2014 Sep 25;159(1):176-187. doi: 10.1016/j.cell.2014.08.016. Epub 2014 Sep 4. Cell. 2014. PMID: 25201530 Free PMC article.
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3. Scher HI, et al. Among authors: slovin sf. J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22. J Clin Oncol. 2016. PMID: 26903579 Free PMC article.
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, Melloni C, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Clarke NW, Olesen TK, Doyle-Olsen BT, Kristensen H, Arney L, Roe MT, Alexander JH; PRONOUNCE Study Investigators. Lopes RD, et al. Among authors: slovin sf. Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30. Circulation. 2021. PMID: 34459214 Free PMC article. Clinical Trial.
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. Abida W, et al. Among authors: slovin sf. JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801. JAMA Oncol. 2019. PMID: 30589920 Free PMC article.
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
Lenis AT, Ravichandran V, Brown S, Alam SM, Katims A, Truong H, Reisz PA, Vasselman S, Nweji B, Autio KA, Morris MJ, Slovin SF, Rathkopf D, Danila D, Woo S, Vargas HA, Laudone VP, Ehdaie B, Reuter V, Arcila M, Berger MF, Viale A, Scher HI, Schultz N, Gopalan A, Donoghue MTA, Ostrovnaya I, Stopsack KH, Solit DB, Abida W. Lenis AT, et al. Among authors: slovin sf. Clin Cancer Res. 2024 Sep 3;30(17):3894-3903. doi: 10.1158/1078-0432.CCR-23-3403. Clin Cancer Res. 2024. PMID: 38949888 Free PMC article.
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.
Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, Niles DJ, Heninger E, Rydzewski NR, Wang L, Wang L, Yang R, Ren Y, Engle JW, Huang P, Kyriakopoulos CE, Slovin SF, Soule HR, Zhao SG, Kohli M, Tagawa ST, Cai W, Dehm SM, Lang JM. Sperger JM, et al. Among authors: slovin sf. Clin Cancer Res. 2023 Jun 13;29(12):2324-2335. doi: 10.1158/1078-0432.CCR-22-1305. Clin Cancer Res. 2023. PMID: 36939530 Free PMC article.
Challenges and recommendations for early identification of metastatic disease in prostate cancer.
Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group. Crawford ED, et al. Among authors: slovin sf. Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8. Urology. 2014. PMID: 24411213 Review.
Immunotherapy in metastatic prostate cancer.
Slovin SF. Slovin SF. Indian J Urol. 2016 Oct-Dec;32(4):271-276. doi: 10.4103/0970-1591.191240. Indian J Urol. 2016. PMID: 27843208 Free PMC article. Review.
143 results